Thursday, September 14, 2023 7:07:31 PM
For its next generation T-cell product candidates, the company will incorporate multiple modular enhancements, but as the authors of this point out engineering multiple features into one cell product is limited by the constraints of current viral vectors, which leads to a heterogeneous population of cells.
Using a leucine zipper-based cell sorting enabled a selective single-step purification of cells co-transduced with two vectors, designed to potentially double the number of incorporated transgenes. This facilitated generation of T-cells simultaneously expressing up to four CARs (CD19, CD20, CD79b, and BAFF-R) and co-expressing up to three switch receptors (CD200R-CD27, PD-1-OX40, and Fas-41BB) https://www.biorxiv.org/content/10.1101/2023.09.13.557232v1
Using a leucine zipper-based cell sorting enabled a selective single-step purification of cells co-transduced with two vectors, designed to potentially double the number of incorporated transgenes. This facilitated generation of T-cells simultaneously expressing up to four CARs (CD19, CD20, CD79b, and BAFF-R) and co-expressing up to three switch receptors (CD200R-CD27, PD-1-OX40, and Fas-41BB) https://www.biorxiv.org/content/10.1101/2023.09.13.557232v1
Recent AUTL News
- Autolus Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/27/2026 11:00:00 AM
- Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 • GlobeNewswire Inc. • 05/21/2026 09:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 11:53:38 AM
- Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:18 AM
- Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 09:28:25 PM
- Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction • GlobeNewswire Inc. • 04/29/2026 08:05:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 08:08:11 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 04/15/2026 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 08:17:09 PM
- Autolus Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 04/07/2026 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:39:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 12:02:10 PM
- Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates • GlobeNewswire Inc. • 03/27/2026 11:00:00 AM
